Patents by Inventor Marlene Thomas

Marlene Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
    Publication number: 20220282337
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 8, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anton Belousov, Giampaolo Bianchini, Luca Gianni, Marlene Thomas
  • IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY
    Publication number: 20220170115
    Abstract: The present invention relates to means and methods for determining whether a patient is in need of a PD-L1 inhibitor cotherapy. A patient is determined to be in need of the PD-L1 inhibitor cotherapy if a low or absent ER expression level and an expression level of programmed death ligand 1 (PD-L1) that is increased in comparison to a control is measured in vitro in a sample from the patient. The patient is undergoing therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) or such a therapy is contemplated for the patient. Also provided herein are means and methods for treating a cancer in a cancer patient for whom therapy comprising a modulator of the HER2/neu (ErbB2) signaling pathway (like Trastuzumab) and a chemotherapeutic agent (like dodetaxel) is contemplated, wherein the patient is to receive PD-L1 inhibitor cotherapy.
    Type: Application
    Filed: February 17, 2022
    Publication date: June 2, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anton Belousov, Giampaolo Bianchini, Luca Gianni, Marlene Thomas
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10336830
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: July 2, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10287358
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 14, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20180346582
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 18, 2018
    Publication date: December 6, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10077314
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 18, 2018
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10072087
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 11, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10030073
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: July 24, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10023643
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: July 17, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 9988458
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: June 5, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 9951139
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 24, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 9951140
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 24, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 9879085
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: January 30, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 9663580
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 30, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
  • Nucleic acids encoding antibodies against human CSF-1R
    Patent number: 9624302
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Nucleic acids encoding antibodies against human CSF-1R and uses thereof
    Patent number: 9617342
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: April 11, 2017
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 9499625
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: November 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 9499624
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Martin Lanzendoerfer, Marlene Thomas, Carola Ries, Stefan Seeber
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 9499626
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: November 22, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber, Martin Lanzendoerfer
  • COMBINATION THERAPY OF ANTI-HER3 ANTIBODIES
    Publication number: 20160159912
    Abstract: The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.
    Type: Application
    Filed: October 7, 2015
    Publication date: June 9, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frieder Bauss, Birgit Bossenmaier, Thomas Friess, Christian Gerdes, Max Hasmann, Marlene Thomas, Martin Weisser